Research
Hormonal
Sulfur amino acid restriction (SAAR) significantly decreases serum leptin levels and increases plasma ketone bodies (beta-hydroxybutyrate and acetoacetate) compared to a control diet, indicating a shift in metabolic fuel usage.
Reducing sulfur amino acids lowers leptin (a hormone that signals fat stores to the brain) and increases ketones. This suggests your body is switching to burning fat for fuel more efficiently, which may help sustain weight loss.
GoodSupportsHIGH confidence
Furthermore, SAAR decreased serum leptin, and increased ketone bodies compared to controls.
Why this rating
Supported by the same RCT data as N1, with statistically significant p-values for leptin and ketones.
Source
Dietary sulfur amino acid restriction in humans with overweight and obesity: a translational randomized controlled trial
Thomas Olsén et al. · Journal of Translational Medicine · 2024
DOI 10.1186/s12967-023-04833-w
rct · n=59Cited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- An 8-week sulfur amino acid restriction (SAAR) diet (~2 g/day) in humans with overweight or obesity produces significantly greater weight loss (~20% greater) compared to a control diet (~5.6 g/day), despite maintaining similar resting metabolic rates.Good
- Sulfur amino acid restriction (SAAR) induces transcriptional remodeling in white adipose tissue (WAT), upregulating ribosomal processes and downregulating structural components, without significantly altering classical metabolic risk biomarkers like lipids or glucose.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →